Infliximab use and cervical spine deformity in patients with rheumatoid arthritis
Main finding · Cervical spine deformity per 1-year increase in duration of infliximab useResult — go to the resultOdds ratio 0.89 95% CI 0.81–0.98Authors' conclusion
There was evidence of a beneficial association between longer duration of use of infliximab and cervical spine deformity after 10 years follow-up.
Study context
- Population
- Patients with new-onset rheumatoid arthritis (RA) followed for 10 years (BeSt trial)
- Participants
- 272 patients
- Comparison
- Duration of infliximab use and cervical spine deformity
- Outcome
- Cervical spine deformity (AAS and/or SAS >2 mm) on lateral X-rays
- Follow-up
- 5-year and 10-year follow-ups
Methodological detailsmultiple logistic regression adjusted for age, gender, baseline Disease Activity Score (DAS44), ACPA-positivity and RF-positivity, mediation analysis via mean DAS44, missing exposure imputed by last observation carried forward
- Multiple logistic regression adjusted for age, gender, baseline DAS44, ACPA-positivity and RF-positivity
- Mediation analysis via mean DAS44
- Missing exposure imputed by last observation carried forward
Main finding
As reported in the abstract
Cervical spine deformity per 1-year increase in duration of infliximab use
Odds ratio
0.89
95% CI 0.81–0.98
P = 0.02
Per 1-year increase in duration of infliximab use
OR 0.89 (95% CI 0.81–0.98); P = 0.02
Per 1-year increase in duration of infliximab, as printed
Observational data: associations, not effects.
Further findings
Mediation via DAS44
- Mediation analysis could not reveal an influence of DAS44 on the association between infliximab use and cervical spine outcomes
Original publication
Infliximab use and cervical spine deformity in patients with rheumatoid arthritis. RMD Open. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →